Lay summary
Advanced diabetes technology and automated insulin delivery is now clearly the gold standard for type 1 diabetes care in New Zealand and worldwide. However, the majority of people with diabetes, particularly adults have yet to access this care due to a variety of reasons. PHARMAC will soon allow unrestricted funding to these systems, but current models of care are unable to cope with the expected demand, a shift from 10-15% use currently to 70-80% use over the coming years (as seen overseas). In addition, if this shift follows current patterns, the increase will largely first occur in those who are European, with already in-target diabetes, with less deprivation, and those living in urban settings. We seek to shift the model of care to allow first, fast, safe, and equitable access to those who need it the most - those out-of-target with a focus on priority populations.